INMB

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027.

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update.  Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million.  This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026.  After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company's net cash used in operating activities during the quarter.  The rebates strengthen the Company's balance sheet and extend its cash runway as INmune Bio advances CORDStrom™ (Ebstrocel™) toward regulatory filings.

Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform.

The study points to soluble TNF as a key biological link between head injury and Alzheimer's disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.

Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom